UNSPSC 51386600: Combination anti-inflammatory agents

This classification denotes combination drugs that reduce or suppress a pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions, and which manifests as pain, heat, redness, swelling, and loss of function, a condition known as inflammation, hence the term ANTI-INFLAMMATORY AGENTS. Typical combination anti-inflammatory agent constituents are alcohol, aluminum hydroxide, dibucaine, esomeprazole, fluocinolone, hydrocortisone, and lansoprazole.

UNSPSC 51386600 Combination anti-inflammatory agents is a Class code under which state and local governments procure pharmaceutical products, including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and related pharmacy benefit program services. The scope of work reflects a shift toward direct-to-manufacturer procurement models and competitive supplier arrangements that reduce reliance on traditional pharmacy benefit managers and wholesaler intermediaries. State and local issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission appear as active solicitors in the recent record.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026 to explore vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling early-stage market assessment before formal procurement. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products across multiple states including Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. Vendors under the MMCAP procurement must maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act requirements, and accept a 3 percent administrative fee on all contract purchases.